Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

Fatih Kuş; Hasan Çağrı Yıldırım; Doğan Bayram; Öznur Bal; Gökhan Şahin; Muzaffer Uğraklı; Atike Gökçen Demiray; Özkan Alan; Ilgın Koç Kuş; Fırat Şirvan; Nilgün Yıldırım; Olçun Ümit Ünal; Şendağ Yaslıkaya; Elif Şahin; Teoman Şakalar; Fatih Atalah; Oğur Karhan; Serkan Enki; Saadettin Kılıçkap; Serkan Akın

doi:10.1080/1120009x.2025.2557678

Key Points

Palbociclib may improve treatment outcomes for patients with well-differentiated and dedifferentiated liposarcoma.
The analysis covers multiple centers and includes a diverse patient population, enhancing the reliability of findings.
Data emphasize the importance of CDK4 amplification in understanding treatment responses in liposarcoma subtypes.
Results from real-world settings indicate that CDK4/6 inhibitors like palbociclib warrant further exploration in clinical practice.

Implication

Observational analysis demonstrates palbociclib's potential in WDLPS and DDLPS, suggesting further research is needed.

Abstract

Background Well-differentiated (WDLPS) and dedifferentiated liposarcomas (DDLPS) are subtypes with distinct behaviors, often driven by CDK4 amplification. While CDK4/6 inhibitors such as palbociclib show promise in trials, real-world data are scarce.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kuş et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3831b076d99fa54c02 https://doi.org/10.1080/1120009x.2025.2557678

View Full Paper

Ask AI

Bookmark

Share

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

Key Points

Implication

Abstract

Discussion

Cite This Study

Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading